Clinical application of targeted tumour sequencing tests for detecting erbb2 amplification and optimizing anti-her2 therapy in gastric cancer

HIGHLIGHTS

• What: The authors aimed to clarify the concordance between ERBB2 CNA detected by a targeted tumour sequencing test and HER2 status evaluated by IHC and FISH using the genomic profile of GC in the previous study . In the present study, compared with no ERBB2 AMP, ERBB2 AMP was associated with better PFS and a higher ORR for trastuzumab therapy. Previous studies have demonstrated that elevated continuous copy numbers of ERBB2 correlate significantly with extended PFS , and higher cut-off values of ERBB2 CNA, compared to those employed in the current study, have proven advantageous for prognostic categorization . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.